東北大学加齢医学研究所　臨床腫瘍学分野　東北大学　腫瘍内科

研究室紹介

HOME < 研究業績 < 英文論文 2017年度

英文論文 2017年度

  1. Miguchi, M.，Hinoi, T.，Tanakaya, K.，Yamaguchi, T.，Furukawa, Y.，Yoshida, T.，Tamura, K.，Sugano, K.，Ishioka, C.，Matsubara, N.，Tomita, N.，Arai, M.，Ishikawa, H.，Hirata, K.，Saida, Y.，Ishida, H.，Sugihara, K.: Alcohol consumption and early-onset risk of colorectal cancer in Japanese patients with Lynch syndrome: a cross-sectional study conducted by the Japanese Society for Cancer of the Colon and Rectum. Surg Today 48. 810-814. Mar 24（2018）
  2. Yamaguchi, S.，Takahashi, S.，Mogushi, K.，Izumi, Y.，Nozaki, Y.，Nomizu, T.，Kakugawa, Y.，Ishida, T.，Ohuchi, N.，Ishioka, C.，Kato, S.: Molecular and clinical features of the TP53 signature gene expression profile in early-stage breast cancer. Oncotarget 9. 14193-14206. Mar 6（2018）
  3. Yamada, Y.，Denda, T.，Gamoh, M.，Iwanaga, I.，Yuki, S.，Shimodaira, H.，Nakamura, M.，Yamaguchi, T.，Ohori, H.，Kobayashi, K.，Tsuda, M.，Kobayashi, Y.，Miyamoto, Y.，Kotake, M.，Shimada, K.，Sato, A.，Morita, S.，Takahashi, S.，Komatsu, Y.，Ishioka, C.: S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. Ann Oncol 29. 624-631. Mar 1（2018）
  4. Bando, H.，Shimodaira, H.，Fujitani, K.，Takashima, A.，Yamaguchi, K.，Nakayama, N.，Takahashi, T.，Oki, E.，Azuma, M.，Nishina, T.，Hironaka, S.，Komatsu, Y.，Shitara, K.: A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer. Eur J Cancer 91. 86-91. Mar（2018）
  5. Horie, S.，Oya, M.，Nangaku, M.，Yasuda, Y.，Komatsu, Y.，Yanagita, M.，Kitagawa, Y.，Kuwano, H.，Nishiyama, H.，Ishioka, C.，Takaishi, H.，Shimodaira, H.，Mogi, A.，Ando, Y.，Matsumoto, K.，Kadowaki, D.，Muto, S.: Guidelines for treatment of renal injury during cancer chemotherapy 2016. Clin Exp Nephrol 22. 210-244. Feb（2018）
  6. Takahashi, H.，Takahashi, M.，Ohnuma, S.，Unno, M.，Yoshino, Y.，Ouchi, K.，Takahashi, S.，Yamada, Y.，Shimodaira, H.，Ishioka, C.: microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer. BMC Cancer 17. 723-737. Nov 07（2017）
  7. Ito, S. E.，Shirota, H.，Kasahara, Y.，Saijo, K.，Ishioka, C.: IL-4 blockade alters the tumor microenvironment and augments the response to cancer immunotherapy in a mouse model. Cancer Immunol Immunother 66. 1485-1496. Nov（2017）
  8. Saijo, K.，Imai, H.，Chikamatsu, S.，Narita, K.，Katoh, T.，Ishioka, C.: Antitumor activity and pharmacologic characterization of the depsipeptide analog as a novel histone deacetylase/ phosphatidylinositol 3-kinase dual inhibitor. Cancer Sci 108. 1469-1475. Jul（2017）
  9. Okada, Y.，Kato, S.，Sakamoto, Y.，Oishi, T.，Ishioka, C.: Synthetic lethal interaction of CDK inhibition and autophagy inhibition in human solid cancer cell lines. Oncol Rep 38. 31-42. Jul（2017）
  10. Hiraide, S.，Ono, S.，Kato, S.: Long-Term Efficacy of S-1 Chemotherapy plus Administration of Octreotide for a Patient with Metastatic Neuroendocrine Tumor (Gastrinoma). Case Rep Oncol 10. 420-427. May-Aug（2017）
  11. Takahashi, M.，Takahashi, M.，Komine, K.，Yamada, H.，Kasahara, Y.，Chikamatsu, S.，Okita, A.，Ito, S.，Ouchi, K.，Okada, Y.，Imai, H.，Saijo, K.，Shirota, H.，Takahashi, S.，Mori, T.，Shimodaira, H.，Ishioka, C.: The G8 screening tool enhances prognostic value to ECOG performance status in elderly cancer patients: A retrospective, single institutional study. PLoS One 12. e0179694. Jun 24（2017）
  12. Takahashi, M.，Komine, K.，Imai, H.，Okada, Y.，Saijo, K.，Takahashi, M.，Shirota, H.，Ohori, H.，Takahashi, S.，Chiba, N.，Mori, T.，Shimodaira, H.，Ishioka, C.: Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis. PLoS One 12. e0176972. May 11（2017）
  13. Shitara, K.，Takashima, A.，Fujitani, K.，Koeda, K.，Hara, H.，Nakayama, N.，Hironaka, S.，Nishikawa, K.，Makari, Y.，Amagai, K.，Ueda, S.，Yoshida, K.，Shimodaira, H.，Nishina, T.，Tsuda, M.，Kurokawa, Y.，Tamura, T.，Sasaki, Y.，Morita, S.，Koizumi, W.: Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol 2. 277-287. Apr（2017）

ページの先頭へ戻る

© 2006 Department of Medical Oncology, Tohoku University Hospital All rights reserved.